Literature DB >> 14520012

Angiotensin-converting enzyme inhibition modulates high-glucose-induced extracellular matrix changes in mouse glomerular epithelial cells.

S Morano1, R Cipriani, M G Cerrito, C Santangelo, F Vasaturo, F Pantellini, M Sensi, L Guidobaldi, S Scarpa, U Di Mario.   

Abstract

BACKGROUND/AIM: Extracellular matrix alterations are involved in the pathogenesis of diabetic nephropathy. We evaluated the effects of high glucose concentrations and inhibition of angiotensin-converting enzyme on the laminin and fibronectin production by glomerular epithelial cells.
METHODS: Glomerular epithelial cells were cultured in 5 and 30 mmol/l glucose, with and without enalaprilat (0.3 mmol/l). Laminin and fibronectin were measured (35S-methionine, immunoprecipitation), and their mRNA expression was evaluated (RT-PCR).
RESULTS: The laminin concentration was higher in the cells than in the medium, where an increase of its content was observed under high-glucose conditions (p < 0.01). Fibronectin, found only in the medium, was not modified by the high glucose concentration. Following enalaprilat administration, the laminin concentration was decreased under high-glucose conditions, both in the cell and in the medium (p < 0.001), whereas the fibronectin concentration was increased under high-glucose conditions (p < 0.001). The mRNA expression of laminin and fibronectin under high-glucose conditions only slightly increased. Enalaprilat decreased the fibronectin mRNA synthesis dramatically (>50%, p < 0.0001) under high-glucose conditions.
CONCLUSIONS: Enalaprilat normalizes the abnormal, high-glucose-induced concentration of laminin, while it decreases the fibronectin synthesis. The improvement of the renal function in diabetic patients treated with angiotensin-converting enzyme inhibitors may, in part, be due to a modulator effect on extracellular matrix content and composition. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14520012     DOI: 10.1159/000073021

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  3 in total

Review 1.  Podocytopathy in diabetes: a metabolic and endocrine disorder.

Authors:  Ana Diez-Sampedro; Oliver Lenz; Alessia Fornoni
Journal:  Am J Kidney Dis       Date:  2011-06-29       Impact factor: 8.860

Review 2.  Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.

Authors:  Kirk N Campbell; Leopoldo Raij; Peter Mundel
Journal:  Curr Diabetes Rev       Date:  2011-01

Review 3.  Dual effects of RAS blockade on blood pressure and podocyte function.

Authors:  Jochen Reiser; Peter Mundel
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.